Thermo Fisher closes Clario deal

Thermo Fisher Scientific closed its acquisition of clinical-trial technology company Clario on March 24, folding a major trial data business into its drug-development services arm. (thermofisher.com) Thermo Fisher said it paid $8.875 billion in cash at closing, with additional earnout and other payments still possible based largely on performance. Clario now sits inside Thermo Fisher’s Laboratory Products and Biopharma Services segment. (thermofisher.com) Clario sells what trial operators call endpoint data tools: systems that capture the measurements regulators use to judge whether a drug worked, such as imaging scans, electronic patient diaries, cardiac safety readings, and motion data from wearables. Its platform combines data from trial sites, devices, and patients across multiple phases of development. (clario.com) (appliedclinicaltrialsonline.com) That puts Thermo Fisher deeper into a part of the drug business that sits between running a study and filing for approval: gathering clean, usable evidence. Thermo Fisher said Clario’s platform supported about 70% of novel-drug approvals by the U.S. Food and Drug Administration and the European Medicines Agency over the past decade. (businesswire.com) The deal also extends Thermo Fisher’s push beyond lab instruments and manufacturing into software and services used by drugmakers from trial design through commercialization. Thermo Fisher bought contract research giant PPD in 2021, and Clario adds another layer inside the clinical-trial workflow. (thermofisher.com) When Thermo Fisher announced the transaction in December 2025, it said the purchase would be immediately accretive to adjusted earnings per share after closing. The company also projected about $175 million of revenue synergies by year five. (thermofisher.com) European regulators cleared the acquisition unconditionally on March 20, according to deal coverage, removing a final obstacle before closing four days later. Trade publication Clinical Trials Arena reported the agreement also includes a $125 million payment due in January 2027 and up to $400 million in earnouts tied to Clario’s 2026 and 2027 performance. (clinicaltrialsarena.com) Clario’s owners at signing were a shareholder group led by Astorg and Nordic Capital, along with Novo Holdings and Cinven. For Thermo Fisher, the closing turns a planned expansion into trial data capture into an operating business with existing pharmaceutical and biotechnology customers. (thermofisher.com)